Indonesia Next Generation Sequencing Market Outlook to 2028

Indonesia Next Generation Sequencing Market Overview

Indonesia Next Generation Sequencing is growing at a rapid pace. Meanwhile, Global Next Generation Sequencing (NGS) market was valued at USD 13 billion in 2023, driven by advancements in genomic research, increasing applications of NGS in diagnostics and personalized medicine, and the growing demand for precision medicine in the region.

The key players in the Indonesia NGS market include Illumina Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Roche Diagnostics and Pacific Biosciences. These companies have established a strong presence through strategic partnerships, product innovations, and expanding their market reach in Indonesia.

In 2022, Illumina Inc. announced a collaboration with the Indonesian Ministry of Health to enhance the country’s genomic capabilities. This partnership aims to establish a national genome center, thereby accelerating genomic research and the adoption of NGS technologies in clinical settings.

Indonesia Next Generation Sequencing Current Market Analysis

Continuous improvements in sequencing technologies, such as the development of high-throughput sequencing platforms, have significantly reduced the cost and time required for sequencing, thus driving market growth.

The growing adoption of NGS has revolutionized the field of genomics, enabling researchers and clinicians to obtain detailed genetic information. This has had a profound impact on personalized medicine, leading to more precise treatments and improved patient outcomes.

Java is the dominant region in the Indonesia NGS market, accounting for a substantial market share in 2023. The region's dominance is due to its advanced healthcare infrastructure, higher concentration of research institutions, and greater awareness and adoption of genomic technologies.

Indonesia Next Generation Sequencing Market Segmentation

By Application: By application, the Indonesia next generation sequencing market is segmented into clinical, research and other applications. In 2023, the clinical segment is dominating the market. Clinical research is dominating due to the rising use of NGS in disease diagnosis, particularly in oncology and genetic disorders, making personalized treatment plans more effective.

By Technology: By technology, the market is segmented into sequencing by synthesis (SBS), ion semiconductor sequencing and single molecule real-time (SMRT) sequencing. In 2023, sequencing by synthesis (SBS) have dominated the market. SBS offers high accuracy and throughput, allowing researchers to sequence large genomes quickly and reliably This is crucial for applications like genetic disease diagnosis and personalized medicine.

By End-User: The market is segmented into hospitals & clinics, academic & research institutions and pharmaceutical & biotechnology companies. In 2023, the Hospitals & Clinics have dominated the market. Hospitals & clinics are dominating due to the direct application of NGS in diagnostics and personalized treatment, leading to better patient outcomes. NGS is a powerful tool for diagnosing a wide range of genetic disorders.

Indonesia Next Generation Sequencing Market Competitive Landscape

Company Name

Establishment Year

Headquarters

Illumina Inc.

1998

San Diego, USA

Thermo Fisher Scientific

2006

Waltham, USA

Agilent Technologies

1999

Santa Clara, USA

Roche Diagnostics

1896

Basel, Switzerland

Pacific Biosciences

2004

Menlo Park, USA

In 2022, Illumina launched its Nova Seq X series, which can generate up to 20 billion reads in a single run, enhancing its market-leading position. The company also reported a revenue increase, reaching over $4 billion, driven by the growing adoption of its sequencing platforms.

In 2021, the acquisition of Qiagen's NGS business has strengthened Thermo Fisher's portfolio, making it a key player in the genomics field, valuing Qiagen at $11.5 billion. Thermo Fisher's NGS segment reported robust growth, contributing significantly to its overall revenue.

Agilent’s focus on precision medicine and its advanced sequencing platforms have bolstered its position in the market. The introduction of Agilent’s Sure Select XT HS2 DNA kit has improved the efficiency and accuracy of NGS, catering to the needs of clinical and research laboratories.

Indonesia Next Generation Sequencing Market Analysis

Indonesia Next Generation Sequencing Market Growth Drivers

Advancements in Sequencing Technologies: The cost of sequencing a human genome has dropped from USD 100 million in 2001 to less than USD 1,000 in 2023. This substantial reduction in cost is driving the adoption of NGS across various applications, including clinical diagnostics, agriculture, and research.

Increasing Prevalence of Genetic Disorders: The rising incidence of genetic disorders in Indonesia is a major growth driver for the NGS market. Around 5 million people in Indonesia are living with a variety of rare genetic diseases, which would make it the 3rd most populous country of rare disease patients. The need for accurate and early diagnosis of these disorders is fueling the demand for NGS, which provides detailed genetic information essential for personalized treatment plans.

Government Support and Initiatives: The Indonesian government has been actively promoting genomic research and the integration of NGS technologies in healthcare. In 2022, the government launched the National Genome Center in collaboration with Illumina Inc., aimed at enhancing the country’s genomic capabilities. The government’s allocation of significant funding for genomic research in 2021 also underscores its commitment to advancing this field.

Indonesia Next Generation Sequencing Market Challenges

High Initial Investment Costs: The high initial investment required for NGS infrastructure and equipment is a significant challenge. Establishing an NGS laboratory involves substantial costs, including purchasing sequencing platforms, computational infrastructure, and hiring skilled personnel.

Data Management and Analysis: Managing and analyzing the vast amounts of data generated by NGS is a complex task. Each sequencing run can produce terabytes of data, requiring robust data management solutions and skilled bioinformaticians to interpret the results.

Ethical and Regulatory Issues: Ethical and regulatory issues related to genetic testing and data privacy pose challenges to the NGS market. The collection, storage, and use of genetic data are subject to strict regulations to protect patient privacy and prevent misuse. Compliance with these regulations is essential but can be cumbersome and time-consuming, potentially hindering the adoption of NGS technologies.

Indonesia Next Generation Sequencing Market Government Initiatives

National Genome Center: In 2022, the Indonesian government launched the National Genome Center in collaboration with Illumina Inc. This initiative aims to enhance the country’s genomic capabilities by providing state-of-the-art sequencing facilities and training programs for researchers and clinicians. The center is expected to accelerate the adoption of NGS technologies in clinical diagnostics and research, contributing to the growth of the NGS market in Indonesia.

Genomic Research Funding: In 2021, the Indonesian government allocated significant funding for genomic research, highlighting its commitment to advancing this field. The funding aims to support various genomic projects, including disease research, personalized medicine, and agricultural genomics.

Integration of Genomic Medicine in Healthcare Policy: The Indonesian government integrated genomic medicine into its national healthcare policy in 2020, emphasizing the importance of genetic testing and personalized medicine. This policy includes guidelines for the use of NGS in clinical diagnostics and encourages healthcare providers to adopt genomic technologies.

Indonesia Next Generation Sequencing Future Market Outlook

The Indonesia NGS market is expected to continue its robust growth, driven by technological advancements, increasing applications in clinical diagnostics, and supportive government initiatives.

Future Market Trends:

Integration of AI & Machine Learning: Integration of artificial intelligence (AI) and machine learning with NGS data analysis is a significant trend. AI and machine learning algorithms will enhance the accuracy and speed of genomic data interpretation, enabling more precise diagnostics and personalized treatments.

Expansion of Liquid Biopsy Applications: The use of NGS in liquid biopsy applications is expanding, offering a non-invasive method for detecting genetic mutations and monitoring disease progression. Liquid biopsies use blood samples to analyze circulating tumor DNA (ct DNA), providing valuable insights into cancer diagnosis and treatment.

Focus on Rare Disease Research: NGS is becoming a crucial tool in rare disease research, enabling the identification of genetic mutations and the development of targeted therapies. The application of NGS in rare disease research is expected to grow, driven by advancements in sequencing technologies and increasing awareness of rare diseases.

Â
Please Note: It will take 5-7 business days to complete the report upon order confirmation